Goldenwell Biotech, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GWLL research report →
About the company
Goldenwell Biotech, Inc. , focuses on nutraceutical and dietary supplements business in the United States. It is developing JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement.
- CEO
- Shuang Liu
- IPO
- 2022
- Employees
- 3
- HQ
- Hudson, OH, US
Price Chart
- Market Cap
- $51.48M
- P/E
- -200.00
- P/S
- 848.18
- P/B
- -149.78
- EV/EBITDA
- -232.04
- Div Yield
- 0.00%
- Gross Margin
- 102.99%
- Op Margin
- -104.18%
- Net Margin
- -379.85%
- ROE
- 100.43%
- ROIC
- -63.45%
- Revenue
- $55 · -60.43%
- Net Income
- $-296,471 · -125.46%
- EPS
- $-0.00 · -130.77%
- Op Income
- $-113,326
- FCF YoY
- 81.61%
- 52W High
- $10.00
- 52W Low
- $0.20
- 50D MA
- $0.69
- 200D MA
- $1.51
- Beta
- 4.75
- Avg Volume
- 273
Get TickerSpark's AI analysis on GWLL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our GWLL coverage
Recent articles, reports, and earnings notes.
No research on GWLL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GWLL report →Similar companies
Peers in the same neighborhood.